SPECIAL NOTICE
65 -- In Vivo Electrochemical Immunoassay
- Notice Date
- 6/7/2005
- Notice Type
- Special Notice
- NAICS
- 339112
— Surgical and Medical Instrument Manufacturing
- Contracting Office
- Department of Energy, Sandia Corp. (DOE Contractor), Sandia National Laboratories, PO Box 5800 MS: 0115, Albuquerque, NM, 87185
- ZIP Code
- 87185
- Solicitation Number
- 05-273
- Response Due
- 7/6/2005
- Archive Date
- 7/6/2005
- Description
- Sandia National Laboratories, the lead research and development laboratory for the Department of Energy?s physical security needs, is seeking one or more business partners in the medical diagnostics field, including but not limited to glucose detection, to engage in the creation of a Cooperative Research and Development Agreement (CRADA) for the further development of Sandia?s ElectroNeedles technology for in vivo electrochemical immunoassays. Commercial licensing of the technology described in this posting will also be considered. Commercial licensees will have the opportunity to obtain, up to and including, an exclusive license to the intellectual properties in pre-negotiated, defined fields of use for reasonable compensation. It is expected that the business partner (or partners) that works with Sandia to develop the ElectroNeedle technology will promptly incorporate it into a commercial analyte detection product. Sandia believes this technology may best be commercialized by medical diagnostics companies with experience in diagnostic systems and with successful product offerings. Potential partners must provide Sandia information describing their ability to research, design, develop, manufacture, distribute, market, and service fully functional diagnostics systems. The subject technology is a platform of individually addressable microelectrodes, capable of painlessly passing into a patient?s skin and accessing interstitial fluid. Various analytes are detected in vivo via electrochemical methods, allowing analytes possessing redox behaviors to be easily detected in real-time without pain to the patient. To date, Sandia has demonstrated glucose detection with this technology. To express interest in this opportunity, please respond by mail or fax to Teresa Montoya by 06 July 2005 at: Sandia National Laboratories, MS 0115, P.O. Box 5800, Albuquerque New Mexico 87185-0115, Fax (505) 844-8011, E-mail: tmontoy@sandia.gov. Please indicate the date and title of the FBO notice. Include company and contact information, as well as a description of how your company meets Sandia?s criteria and could best contribute to the formation of a CRADA partnership or license and the subsequent commercialization of this technology.
- Place of Performance
- Address: PO Box 5800, Albuquerque, NM,
- Zip Code: 87185
- Country: USA
- Zip Code: 87185
- Record
- SN00823938-W 20050609/050607211720 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |